Nanovi APS
Injectable liquid tissue marker for improved radiation precision
This article was originally published in Start Up
Executive Summary
The unavailability of a good fiducial marker for pre-treatment image planning and subsequent image-guided radiotherapy is currently a major obstacle to enhancing radiotherapy standards. Copenhagen, Denmark-based start-up Nanovi APS has developed an injectable, liquid, biomaterials-based tissue marker that promises to improve accuracy in IGRT of several types of cancer, including lung cancer.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.